For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
One antibody is specific to the ß-secretase cleavage site at the N-terminus: mouse monoclonal antibody, clone number 82E1. The second antibody is specific to amino acids 17-24: mouse monoclonal antibody, clone number 4G8.
Amyloid beta (Aß) is a short peptide derived from the proteolysis of a larger transmembrane molecule, the amyloid precursor protein (APP). The ß- and ?-secretases cleave the respective N- and C-terminal ends of the Aß sequence, liberating the Aß peptide from APP. Aß40 is the major species of Aß produced by neurons and other cells, and accounts for over 70% of total Aß produced, while the remaining is comprised of the longer Aß42, and other species ranging from 36 to 43 amino acids. Aß42 has a greater propensity to form aggregates or fibrils and also has a greater neuronal toxicity in tissue culture models than Aß40, implying that Aß42 is a more important factor in Alzheimer's disease (AD) pathogenesis and plaque formation. Levels of Aß42 in cerebrospinal fluid are decreased in the majority of AD subjects (probably due to its aggregation into plaques), making it an important biomarker for this disease.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
For the detection of three biomarkers in complex sample matrices, the AlphaLISA and Electrochemiluminescent (ECL) assay technologies were shown to have similar: Assay windows (linear dynamic range), Lower and upper detection limit, Intra-and inter-assay precision (lower % CV) The advantages of using AlphaLISA over ECL are: Shorter total assay duration No wash steps No shaking Lower sample volume requirement for equivalent performance Less expensive instrument and plates required
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.